医学
慢性阻塞性肺病
金标准(测试)
心脏病学
运动不耐症
临床终点
内科学
通风(建筑)
阻塞性肺病
耐力训练
气道
随机对照试验
麻醉
心力衰竭
机械工程
工程类
作者
Keisuke Miki,Kazuyuki Tsujino,Motonari Fukui,Mari Miki,Takamasa Kitajima,Hitoshi Sumitani,Kazuki Hashimoto,M. Yokoyama,Hisako Hashimoto,Takuro Nii,Takahiro Matsuki,Hiroshi Kida
出处
期刊:Thorax
[BMJ]
日期:2023-09-11
卷期号:79 (1): 23-34
标识
DOI:10.1136/thorax-2022-219755
摘要
Rationale Despite strategies acting on peripheral airway obstruction in chronic obstructive pulmonary disease (COPD), exercise intolerance remains inadequately improved. We hypothesised that laryngeal narrowing is a potential treatment target of expiratory pressure load training (EPT) to improve exercise intolerance in COPD. Methods The effect of 3-month EPT was assessed in 47 patients with COPD divided into Global Initiative for Chronic Obstructive Lung Disease (GOLD) mild-to-moderate (I–II) and severe-to-very severe (III–IV), randomly allocating 1:1 to EPT or control groups. The primary outcome was endurance time in the constant work rate exercise test in GOLD III–IV patients. Results Compared with controls, EPT increased: (1) endurance time, with estimated treatment effect: +703 (95% CI: 379 to 1031) s, p=0.0008 (GOLD I–II); +390 (95% CI: 205 to 574) s, p=0.0006 (GOLD III–IV); (2) peak oxygen uptake (p=0.0086 in GOLD I–II; p=0.0004 in GOLD III–IV); (3) glottic dilatation ratio at maximum collapse on laryngoscopy in the submaximal exercise (p=0.0062 in GOLD I–II; p=0.0001 in GOLD III–IV); and (4) the inflection point of expiratory tidal volume relative to minute ventilation during the incremental exercise (p=0.0015 in GOLD I–II; p=0.0075 in GOLD III–IV). Across GOLD grades, the responses of glottic dilatation ratio at maximum collapse and the expiratory tidal volume at the inflection point were selected as more influential variables correlating with the improvement in peak oxygen uptake and endurance time, respectively. Conclusion These results show that EPT improved aerobic capacity and endurance time with larger laryngeal widening and adequate ventilation despite advanced COPD. Trial registration number UMIN000041250.
科研通智能强力驱动
Strongly Powered by AbleSci AI